Avalo Therapeutics Inc

Change company Symbol lookup

Select an option...

AVTX Avalo Therapeutics Inc

EWA iShares MSCI Australia ETF

WDAY Workday Inc

BNOX Bionomics Ltd

NRDY Nerdy Inc

KEY KeyCorp

AMPX Amprius Technologies Inc

TPC Tutor Perini Corp

LTRN Lantern Pharma Inc

JGGC Jaguar Global Growth Corporation I

Go

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the treatment of immune dysregulation by developing therapies that target the Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT)-signaling network. Its clinical-stage pipeline includes AVTX-002, AVTX-008, and AVTX-803 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, Crohn’s Disease, and COVID-19 acute respiratory distress syndromes. AVTX-008 is a fully human B and T lymphocyte attenuator (BTLA) agonist fusion protein that is being evaluated for several immune dysregulation disorders. AVTX-803 is a monosaccharide therapy for the treatment of leukocyte adhesion deficiency type II (LAD II), which is a congenital disorder of glycosylation (CDG).